Eton Pharmaceuticals, Inc. ETON Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 54.8%+1.3pp | 53.5%+2.1pp | 51.4%-8.0pp | 59.4%+0.9pp | 58.5%-1.5pp | |
| Efficiency | ||||||
| Asset turnover | 1×0.0× | 1×-0.1× | 1×+0.1× | 0.9×0.0× | 0.8×+0.1× | |
| Inventory turnover | 2.8×+0.4× | 2.4×-1.2× | 3.6×+1.8× | 1.8×-0.7× | 2.5×+0.6× | |
| Liquidity | ||||||
| Current ratio | 1.2×-0.4× | 1.6×-0.1× | 1.6×-0.1× | 1.8×-0.2× | 2×-0.1× | |
| Quick ratio | 0.9×-0.3× | 1.2×-0.1× | 1.2×+0.1× | 1.2×-0.3× | 1.4×+0.1× | |
| Cash ratio | 0.4×-0.2× | 0.7×-0.2× | 0.8×+0.2× | 0.7×0.0× | 0.7×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 1×-0.2× | 1.2×-0.1× | 1.3×+0.1× | 1.3×0.0× | 1.2×0.0× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×-0.1× | 0.4×0.0× | |
| Valuation | ||||||
| Market capitalization | $953.8M+162% | $453.48M-22.2% | $582.75M+59.9% | $364.45M+4.7% | $348.09M+0.3% | |
| Enterprise value | $965.4M+156% | $458.63M-20.4% | $576.5M+55.9% | $369.77M+2.5% | $360.83M-0.3% | |
| Price / sales | 11×+3.4× | 5.7×-2.6× | 8.3×+2.0× | 6.3×-0.9× | 7.2×-1.7× | |
| Price / book | 31.2×+16.3× | 17.3×-7.9× | 25.2×+10.0× | 15.2×+1.0× | 14.2×0.0× | |
| EV / sales | 11.1×+3.3× | 5.7×-2.5× | 8.2×+1.8× | 6.4×-1.1× | 7.5×-1.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Eton Pharmaceuticals, Inc.'s profit margins?
- Eton Pharmaceuticals, Inc. (ETON) runs a 54.8% gross margin and a -15.1% operating margin, with a -9.5% net margin.
- Where do Eton Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Eton Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
